GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tonix Pharmaceuticals Holding Corp (NAS:TNXP) » Definitions » Tax Rate %

TNXP (Tonix Pharmaceuticals Holding) Tax Rate % : 0.00% (As of Dec. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Tonix Pharmaceuticals Holding Tax Rate %?

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Tonix Pharmaceuticals Holding's Tax Expense for the three months ended in Dec. 2024 was $0.00 Mil. Tonix Pharmaceuticals Holding's Pre-Tax Income for the three months ended in Dec. 2024 was $-22.07 Mil. Therefore, Tonix Pharmaceuticals Holding's Tax Rate % for the quarter that ended in Dec. 2024 was 0.00%.

Tonix Pharmaceuticals Holding Tax Rate % Historical Data

The historical data trend for Tonix Pharmaceuticals Holding's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tonix Pharmaceuticals Holding Tax Rate % Chart

Tonix Pharmaceuticals Holding Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Tax Rate %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Tonix Pharmaceuticals Holding Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Tonix Pharmaceuticals Holding Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Tonix Pharmaceuticals Holding's Tax Rate % for the fiscal year that ended in Dec. 2024 is calculated as

Tax Rate %=Tax Expense (A: Dec. 2024 )/Pre-Tax Income (A: Dec. 2024 )
=0/-130.036
=0.00 %

Tonix Pharmaceuticals Holding's Tax Rate % for the quarter that ended in Dec. 2024 is calculated as

Tax Rate %=Tax Expense (Q: Dec. 2024 )/Pre-Tax Income (Q: Dec. 2024 )
=0/-22.065
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tonix Pharmaceuticals Holding Tax Rate % Related Terms

Thank you for viewing the detailed overview of Tonix Pharmaceuticals Holding's Tax Rate % provided by GuruFocus.com. Please click on the following links to see related term pages.

Tonix Pharmaceuticals Holding Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tonix Pharmaceuticals Holding Corp (NAS:TNXP) » Definitions » Tax Rate %
Comparable Companies
ZNTL TLSA ALEC CSBR MCRB GLSI CCCC ELTX LXEO NKTR VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
26 Main Street, Suite 101, Chatham, NJ, USA, 07928
Website
https://www.tonixpharma.com
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
Executives
Richard Newcomb Stillwell director C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Seth Lederman director, 10 percent owner, officer: Chief Executive Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Carolyn E. Taylor director C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Daniel Wintner Goodman director C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE, NEW YORK NY 10022
James Treco director C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., NEW YORK NY 10022
Margaret Smith Bell director C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Gregory M Sullivan officer: Chief Medical Officer C/O TONIX PHARMACEUTICALS HOLDINGS CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Richard H Bagger director C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE. - SUITE 1608, NEW YORK NY 10022
Adeoye Y Olukotun director 3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
David L Grange director
Ernest Mario director 20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Jessica Edgar Morris officer: Chief Administrative Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Bradley Saenger officer: Chief Financial Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
John B Rhodes director 74 FIFTH AVENUE, NEW YORK NY 10011
Samuel R Saks director 3180 PORTER DRIVE, PALO ALTO CA 94304